Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

uthorized generic version of ESTROSTEP FE. OVCON net sales declined $1.9 million, or 37.2%, in the quarter ended December 31, 2007 compared with the prior year quarter. The decline in OVCON revenues was primarily due to the introduction of generic versions of OVCON 35 beginning in late October 2006, which led to an 83.3% decline in filled prescriptions in the quarter ended December 31, 2007 compared to the prior year quarter. This decline was partially offset by price increases.

Sales of our dermatology products increased $12.6 million, or 14.3%, in the quarter ended December 31, 2007 compared to the prior year quarter, primarily due to a $7.5 million increase in TACLONEX sales. Filled prescriptions for TACLONEX increased 33.8% compared to the prior year quarter. Sales of DORYX increased $4.5 million, or 16.4%, in the quarter ended December 31, 2007, compared with the prior year quarter due to increased demand and higher average selling prices. DORYX prescriptions had been declining through the first half of 2007. In January 2007, we took steps to increase our Dermatology sales force's emphasis on DORYX and those changes resulted in filled prescriptions of DORYX increasing 4.8% in the quarter ended December 31, 2007, compared to the prior year quarter. Sales of DOVONEX increased $0.6 million, or 1.6%, in the quarter ended December 31, 2007 compared with the prior year quarter as price increases more than offset a 23.0% decline in filled prescriptions.

Sales of our hormone therapy products increased $2.5 million, or 6.4%, in the quarter ended December 31, 2007, compared with the prior year quarter. FEMHRT filled prescriptions were down 12.9% in the quarter ended December 31, 2007, compared with the prior year quarter. The impact of this decrease was partially offset by higher selling prices. Sales of ESTRACE CREAM increased due to higher average selling prices, although filled prescriptions were flat in the quarter ended December 31, 2007 compared with
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ... and share analysis. , Full Copy of ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Pipette.com announces ... their Twitter followers can submit their #HolidayInTheLab pictures for ... their lab mates. , For those struggling to think ... the Pipette.com Holiday in the Lab Contest provides the ... Twitter followers to send pictures of their chemistree, ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... Azur Pharma Limited ("Azur,Pharma") today announced that ... Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R),(carbidopa-levodopa orally ... Fluxid(TM) (famotidine orally,disintegrating tablets) from UCB (Euronext: ... Niravam, Parcopa and Kemstro ...
... The readers of The IN VIVO Blog , which ... device industries, have selected a Deal of the Year ... with Takeda Pharmaceuticals .More than 2,500 reader votes were cast ... start to finish among the 13 nominees selected by The ...
... (Nasdaq: MATK ) announced today that it will ... conference. The conference is being held January 14-15, 2009 ... Dana Point, California. Peter L. Buzy, Chief Financial Officer, ... 14, 2009 at 1:25 PM PT.A live audio webcast of ...
Cached Biology Technology:Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB 2The IN VIVO Blog Selects First Annual 'Deal of the Year' 2
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... of Medicine have just developed an advanced imaging technique ... or white blood cells. Microdomains are restricted areas on ... signaling molecules accumulate during cell activation. Using digital multi-channel ... subsets and their forming microdomains in the vascular system ...
... single-walled carbon nanotubes (SWCNTs) shorter than about 200 nanometers ... pose an increased risk to health, according to scientists ... The results of their laboratory studies appear in an ... uses ranging from electronic displays to fuel cells to ...
... of Michigan analytical chemist Kristina Hakansson sets the stage ... growing body of evidence points to assemblies of sugars ... as accomplices in the growth and spread of tumors. ... traditional analytical methods have not been sufficient. , ...
Cached Biology News:New imaging technique tracks traffic patterns of white blood cells 2Cells selectively absorb short nanotubes 2A sweet step toward new cancer therapies 2
Rab1A...
Request Info...
Request Info...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: